Kardiopulmonale Interaktionen: Kardiovaskuläre Erkrankungen und COPD

Schlüsselwörter

chronisch obstruktive Lungenerkrankung - COPD - kardiovaskuläre Erkrankungen - Herzinsuffizienz - Rauchen - Komorbidität

Keywords

chronic obstructive pulmonary disease - COPD - cardiovascular diseases - chronic heart failure - smoking - comorbidity

Literatur

• 1 Alexeeff S E, litonjua A A, Sparrow D. et al . Statin use reduces decline in lung function. VA Normative Aging Study.  Am J Respir Crit Care Med. 2007;  176 742-47
• 2 Augusti A, Thomas A. Neff Lecture. Chronic obstructive pulmonary disease: a systemic disease.  Proc Am Thorac Soc. 2006;  3 478-81
• 3 Baigent C, Keech A, Kearney P M. et al . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins.  Lancet. 2005;  366 1267-78
• 4 Boyd C M, Darer J, Boult C. et al . Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.  JAMA. 2005;  294 716-24
• 5 Bozkanat E, Tozkoparan E, Baysan O. et al . The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease.  J Intern Med Res. 2005;  33 537-544
• 6 Calverly P MA, Anderson J A, Celli B. et al . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.  N Engl J Med. 2007;  356 775-89
• 7 Cazzola M, Imperatore F, Salzillo A. et al . Cardiac effects of Formoterol and Salmeterol in Patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia.  Chest. 1998;  114 411-415
• 8 Chan E D, King T E. Pulmonary disease induced by cardiovascular drugs. 2007 www.uptodate.com
• 9 Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement.  Am Heart J. 1991;  121 1244-63
• 10 European Society of Cardiology, Heart Failure Association of the ESC, European Society of Intensive Care Medicine et al . ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008.  Eur J Heart Fail. 2008;  10 933-989
• 11 Fabbri L M, Luppi F, Beghe B, Rabe K F. Complex chronic comorbidities of COPD.  Eur Respir J. 2008;  31 204-12
• 12 Fabbri L M, Rabe K F. From COPD to chronic systemic inflammatory syndrome?.  Lancet. 2007;  370 797-99
• 13 Funk G C, Lang I, Schenk P. et al . Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure.  Chest. 2008;  133 1354-59
• 14 Gissi-HF, Tavazzi L, Maggioni A P. Investigators, et al . Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.  Lancet. 2008;  372 1231-39
• 15 Groenwegen K H, Postma D S, Hop W CJ. et al . Increased systemic inflammation is a risk factor for COPD exacerbations.  Chest. 2008;  133 350-57
• 16 Hansson G K. Inflammation, atherosclerosis, and coronary artery disease.  N Engl J Med. 2005;  352 1685-95
• 17 Hawkins N M, Petrie M C, Jhund P S. et al . Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology.  Eur J Heart Fail. 2009;  11 130-39
• 18 Hole D J, Watt G C, Davey-Smith G. et al . Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study.  BMJ. 1996;  313 711-15
• 19 Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD.  Eur Respir J. 2005;  25 634-39
• 20 Ito K, Barnes P J. COPD as a disease of accelerated lung aging.  Chest. 2009;  135 173-80
• 21 Kjekshus J, Apetrei E, Barrios V. et al . Rosuvastatin in older patients with systolic heart failure.  N Engl J Med. 2007;  357 2248-61
• 22 Lee S H, Goswami S, Grudo A. et al . Antielastin autoimmunity in tobacco smoking-induced emphysema.  Nat Med. 2007;  13 567-69
• 23 Le J emtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.  J Am Coll Cardiol. 2007;  49 171-80
• 24 Liuzzo G, Biasucci L M, Gallimore J R. et al . The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.  N Engl J Med. 1994;  331 417-424
• 25 Macie C, Wooldrage K, Manfreda J, Anthonisen N R. Inhaled corticosteroids and mortality in COPD.  Chest. 2006;  130 640-46
• 26 Nagaya N, Nishikimi T, Uematsu M. et al . Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.  Circulation. 2000;  102 865-870
• 27 Pai J K, Pischon T, Ma J. et al . Inflammatory markers and the risk of coronary heart disease in men and women.  N Engl J Med. 2004;  351 2599-2610
• 28 Rabe K F, Hurd S, Anzueto A, Barnes P J. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.  Am J Respir Crit Care Med. 2007;  176 532-555
• 29 Rutten F H, Cramer M M, Grobbee D E. Unrecognized heart failure in eldery patients with stable chronic obstructive pulmonary disease.  Eur Heart J. 2005;  26 1887-94
• 30 Salpeter S R, Ormiston T, Salpeter E E. Cardiovascular effects of β-agonists in patients with asthma and COPD. A meta-analysis.  Chest. 2004;  125 2309-21
• 31 Salpeter S R, Ormiston T, Salpeter E E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002 2: CD003566
• 32 Sevenoaks M J, Stockley R A. Chronic obstructive pulmonary disease, inflammation and co-morbidity – a common inflammatory phenotype?.  Respir Res. 2006;  7 70
• 33 Silver M A, Maisel A, Yancy C W. et al . BNP consensus panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular disease.  Congest Heart Fail. 2004;  10 1-30
• 34 Sin D D, Anthonisen N R, Soriano J B, Agusti A G. Mortality in COPD: role of comorbidities.  Eur Respir J. 2006;  28 1245-57
• 35 Singh S, Loke Y, Furberg C. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease.  JAMA. 2008;  300 1439-50
• 36 Soyseth V, Brekke P H, Smith P, Omland T. Statin use is associated with reduced mortality in COPD.  Eur Respir J. 2007;  29 279-83
• 37 Suissa S, Assimes T, Ernst P. Inhaled short acting β agonist use in COPD and the risk of acute myocardial infarction.  Thorax. 2003;  58 43-46
• 38 Takabatake N, Nakamura H, Abe S. et al . The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  161 1179-84
• 39 Tashkin D P, Celli B, Senn S. et al . A 4-year trial of Tiotropium in chronic obstructive pulmonary disease.  N Engl J Med. 2008;  358 1543-54
• 40 The CAPRICORN investigators . Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.  Lancet. 2001;  357 1385-90
• 41 The CIBIS II investigators and committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.  Lancet. 1999;  353 9-13
• 42 van der Woude H, Zaagsma J, Postma D S. et al . Detrimental effects of β-blockers in COPD.  Chest. 2005;  127 818-24
• 43 Walter R E, Wilk J B, Larson M G. et al . Systemic inflammation and COPD. The Framingham Heart Study.  Chest. 2008;  133 19-25
• 44 Watz H, Waschki B, Boehme C. et al . Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity.  Am J Resp Crit Care Med. 2008;  177 743-51